Matthew Read comments on reverse mergers of RTW’s unlisted holdings in Helen Kirrane’s article:
“The real test will be whether these newly listed businesses can sustain their valuations, deliver successful clinical results and ultimately generate profitable exits for shareholders.”
Read the article here